These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 36181766)

  • 1. Efficacy of MSC in Patients with Severe COVID-19: Analysis of the Literature and a Case Study.
    Grumet M; Sherman J; Dorf BS
    Stem Cells Transl Med; 2022 Nov; 11(11):1103-1112. PubMed ID: 36181766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
    Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
    Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics.
    Qin H; Zhao A
    Protein Cell; 2020 Oct; 11(10):707-722. PubMed ID: 32519302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial.
    Zarrabi M; Shahrbaf MA; Nouri M; Shekari F; Hosseini SE; Hashemian SR; Aliannejad R; Jamaati H; Khavandgar N; Alemi H; Madani H; Nazari A; Amini A; Hassani SN; Abbasi F; Jarooghi N; Fallah N; Taghiyar L; Ganjibakhsh M; Hajizadeh-Saffar E; Vosough M; Baharvand H
    Stem Cell Res Ther; 2023 Jun; 14(1):169. PubMed ID: 37365605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential.
    Gorman E; Millar J; McAuley D; O'Kane C
    Expert Rev Respir Med; 2021 Mar; 15(3):301-324. PubMed ID: 33172313
    [No Abstract]   [Full Text] [Related]  

  • 6. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.
    Hashemian SR; Aliannejad R; Zarrabi M; Soleimani M; Vosough M; Hosseini SE; Hossieni H; Keshel SH; Naderpour Z; Hajizadeh-Saffar E; Shajareh E; Jamaati H; Soufi-Zomorrod M; Khavandgar N; Alemi H; Karimi A; Pak N; Rouzbahani NH; Nouri M; Sorouri M; Kashani L; Madani H; Aghdami N; Vasei M; Baharvand H
    Stem Cell Res Ther; 2021 Jan; 12(1):91. PubMed ID: 33514427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review and meta-analysis of mesenchymal stromal/stem cells as strategical means for the treatment of COVID-19.
    Taufiq H; Shaik Fakiruddin K; Muzaffar U; Lim MN; Rusli S; Kamaluddin NR; Esa E; Abdullah S
    Ther Adv Respir Dis; 2023; 17():17534666231158276. PubMed ID: 37128999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Visualized Analyses of Investigations Upon Mesenchymal Stem/stromal Cell-based Cytotherapy and Underlying Mechanisms for COVID-19 Associated ARDS.
    Aitong W; Leisheng Z; Hao Y
    Curr Stem Cell Res Ther; 2022; 17(1):2-12. PubMed ID: 34254927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
    Lanzoni G; Linetsky E; Correa D; Messinger Cayetano S; Alvarez RA; Kouroupis D; Alvarez Gil A; Poggioli R; Ruiz P; Marttos AC; Hirani K; Bell CA; Kusack H; Rafkin L; Baidal D; Pastewski A; Gawri K; Leñero C; Mantero AMA; Metalonis SW; Wang X; Roque L; Masters B; Kenyon NS; Ginzburg E; Xu X; Tan J; Caplan AI; Glassberg MK; Alejandro R; Ricordi C
    Stem Cells Transl Med; 2021 May; 10(5):660-673. PubMed ID: 33400390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment.
    Aghayan HR; Salimian F; Abedini A; Fattah Ghazi S; Yunesian M; Alavi-Moghadam S; Makarem J; Majidzadeh-A K; Hatamkhani A; Moghri M; Danesh A; Haddad-Marandi MR; Sanati H; Abbasvandi F; Arjmand B; Azimi P; Ghavamzadeh A; Sarrami-Forooshani R
    Stem Cell Res Ther; 2022 Jul; 13(1):365. PubMed ID: 35902979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical progress in MSC-based therapies for the management of severe COVID-19.
    Rossello-Gelabert M; Gonzalez-Pujana A; Igartua M; Santos-Vizcaino E; Hernandez RM
    Cytokine Growth Factor Rev; 2022 Dec; 68():25-36. PubMed ID: 35843774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigational Use of Mesenchymal Stem/Stromal Cells and Their Secretome as Add-On Therapy in Severe Respiratory Virus Infections: Challenges and Perspectives.
    Mattoli S; Schmidt M
    Adv Ther; 2023 Jun; 40(6):2626-2692. PubMed ID: 37069355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial.
    Grégoire C; Layios N; Lambermont B; Lechanteur C; Briquet A; Bettonville V; Baudoux E; Thys M; Dardenne N; Misset B; Beguin Y
    Front Immunol; 2022; 13():932360. PubMed ID: 35860245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesenchymal stromal cells to fight SARS-CoV-2: Taking advantage of a pleiotropic therapy.
    Barros I; Silva A; de Almeida LP; Miranda CO
    Cytokine Growth Factor Rev; 2021 Apr; 58():114-133. PubMed ID: 33397585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of Stem Cell Therapy for Acute Respiratory Distress Syndrome with Focus on COVID 19.
    Kaye RJ
    Pain Physician; 2020 Aug; 23(4S):S421-S432. PubMed ID: 32942797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesenchymal stromal cell therapy for COVID-19 acute respiratory distress syndrome: a double-blind randomised controlled trial.
    Martínez-Muñoz ME; Payares-Herrera C; Lipperheide I; Malo de Molina R; Salcedo I; Alonso R; Martín-Donaire T; Sánchez R; Zafra R; García-Berciano M; Trisán-Alonso A; Pérez-Torres M; Ramos-Martínez A; Ussetti P; Rubio JJ; Avendaño-Solà C; Duarte RF
    Bone Marrow Transplant; 2024 Jun; 59(6):777-784. PubMed ID: 38409332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesenchymal stromal/stem cells (MSCs) and MSC-derived extracellular vesicles in COVID-19-induced ARDS: Mechanisms of action, research progress, challenges, and opportunities.
    Moradinasab S; Pourbagheri-Sigaroodi A; Zafari P; Ghaffari SH; Bashash D
    Int Immunopharmacol; 2021 Aug; 97():107694. PubMed ID: 33932694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial.
    Kaffash Farkhad N; Sedaghat A; Reihani H; Adhami Moghadam A; Bagheri Moghadam A; Khadem Ghaebi N; Khodadoust MA; Ganjali R; Tafreshian AR; Tavakol-Afshari J
    Stem Cell Res Ther; 2022 Jun; 13(1):283. PubMed ID: 35765103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial.
    Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; O'Kane C; McAuley DF
    Trials; 2020 Jun; 21(1):462. PubMed ID: 32493473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MSC-NTF (NurOwn®) exosomes: a novel therapeutic modality in the mouse LPS-induced ARDS model.
    Kaspi H; Semo J; Abramov N; Dekel C; Lindborg S; Kern R; Lebovits C; Aricha R
    Stem Cell Res Ther; 2021 Jan; 12(1):72. PubMed ID: 33468250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.